



## Oral Squamous Cell Carcinoma: Molecular Signaling Pathways and Novel Biomarkers

Guest Editor:

**Dr. Sadhna Aggarwal**

University of Texas MD Anderson  
Cancer Center, Houston, TX  
77030, USA

Deadline for manuscript  
submissions:

**31 July 2024**

### Message from the Guest Editor

Oral squamous cell carcinoma (OSCC) is the most common malignant neoplasm of the oral cavity, posing significant challenges in terms of diagnosis, treatment, and prognosis. Understanding the intricate molecular mechanisms and identifying reliable biomarkers is crucial for improved early detection, diagnosis, and targeted therapy.

The scope of this Special Issue includes the exploration of molecular signaling pathways involved in OSCC development, progression, and metastasis. It will unfold the dysregulation of key signaling pathways, including but not limited to the Notch, Wnt/ $\beta$ -catenin, PI3K/AKT, MAPK, and NF- $\kappa$ B pathways. Emphasis will be placed on elucidating the cross-talk between these pathways and their impact on tumour growth, invasion, angiogenesis, metastasis, and immune response modulation.

Additionally, contributions may include studies on genetic, epigenetic, transcriptomic, proteomic, and metabolomic biomarkers. By bringing together the latest advancements in this field, this Special Issue aims to contribute to the understanding of OSCC pathogenesis and innovative treatment strategies for improved patient outcomes.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)